AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05143905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive placebo by SC injection
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product D with 1.5% nicotine
Description: P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT05924581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment of spinal stiffness
Description: The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions.
Study NCT04447300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard power application
Description: Standard power application
Study NCT06254092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tourniquet binding of cervical
Description: The procedure will be performed by surgeons with rich experience in clinical work
Study NCT05088330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: treatment with D-VRD in NDMM
Study NCT05351177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
Study NCT05606848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Emulsion (TPF-T)
Description: All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy.
Study NCT05606848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foods for special medical purposes [FSMP] for patients with tumors
Description: All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy.
Study NCT06176781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol Sequential Therapy
Description: Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
Study NCT06176781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
Study NCT05424796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostasis and cavity disinfection with KTP laser
Description: Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product E with 1.5% nicotine
Description: P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT05770427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make the Connection® Online Program
Description: Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment.
Study NCT06463977 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: The study consisted of a 3 × 3 online factorial experiment employing a survey instrument hosted via Qualtrics presenting describing three patient vignettes. The three patient vignettes varied by various clinical characteristics including age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. Each patient had advanced non-small cell lung cancer (aNSCLC). Each vignette had two parts: Part 1 described the case history for one of the three patients, after which prognostic estimates and medical decision-making was assessed (i.e. 1, 2, 3). Part 2 immediately followed and described the same vignette from the same patient with added information from a hypothetical ML predictive algorithm (i.e. A, B, C). The order of the vignettes in each survey was randomized with regard to presentation strategies for the ML risk predictions, so that there were 6 versions of the survey to which each participant was randomized.
Study NCT05616754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Description: The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
Study NCT05616754 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Description: This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
Study NCT06189534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
Study NCT06301204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: tranexamic acid administration 250mg or 500 mg
Study NCT06301204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: onyl ıv saline (NaCl 0.09%)
Study NCT05655819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: 5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
Study NCT05655819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder dissolved in 8 ounces of water or juice prior to drinking, taken orally three times per day. Looks exactly like the study drug, but it contains no active ingredient.
Study NCT04966520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)
Description: Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients.~Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be \~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days.
Study NCT05901285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAX014
Description: Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
Study NCT05391750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study NCT05391750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06510205 — intervention group
Intervention type: DEVICE
Intervention: Mentor Breast implants
Description: Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form.
Study NCT06423677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Posterior Superior Intercostal Plane Block
Description: The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.
Study NCT06423677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled analgesia
Description: intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
Study NCT06069726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: One dose of atezolizumab will be given prior to resection.
Study NCT05540678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FibreGum
Description: To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
Study NCT05540678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
Study NCT05681884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
Study NCT06373146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT06373146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab
Description: Administered SC
Study NCT06373146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide-Placebo
Description: Administered SC
Study NCT06373146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mibavademab-Placebo
Description: Administered SC
Study NCT06790901 — intervention group
Intervention type: PROCEDURE
Intervention: LUNG ULTRASOUND
Description: Determination of atelectsis By Lung Ultrasound Score
Study NCT06792344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cells
Description: Intravenous injection the targeting CD19 CAR T cell
Study NCT06792344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cells
Description: CD19-targeting CAR-T cells
Study NCT06785844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (Botox )
Description: Botulinum Toxin injection
Study NCT05723198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT05723198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06792162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carilizumab and Apatinib
Description: After every 2 cycles of meparticipants. Apatinib was discontinued for one cycle and an additional course of Carilizumab was administered in preparation for surgery. The time between the last dose and surgery was 3-6 weeks, with a maximum of 6 weeks. Both surgical and non-surgical participants will continue to receive treatment with the original regimen of Carilizumab combined with Apatinib after surgery until disease progression, recurrence, or death, for a maximum of 2 years.
Study NCT06790927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The doctor prescribes medication for patients and follow-up every 3 months
Study NCT06790927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
Study NCT06792357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vagal Active Tone Application Procedure
Description: First section; A video will be created that includes pictures and visuals describing the vagus nerve, explaining its benefits, and providing information about its effects and usage during the birth process.~Second section; Deep breathing and focus exercises;~Feather Breath:~Candle Breath: The pregnant woman inhaled and exhaled as if she was trying to blow out a candle.~Relaxation Breath: Deep breath Third section; Body relaxation exercises; Fourth section; Facial muscle relaxation exercises; Fifth section; Neck and larynx muscle relaxation exercises;
Study NCT04932122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal wrist ganglion alone (DWG)
Description: Patients assigned to this arm will undergo dorsal wrist ganglion cyst excision alone.
Study NCT06133205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catgut Embedding at acupoints
Description: Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
Study NCT06133205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Catgut Embedding at acupoints
Description: Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
Study NCT05528354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN and DEC based conditioning regimen
Description: Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days.
Study NCT05528354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC
Description: In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)>95%.~If the MRD turns positive, DLI can be performed.
Study NCT04932122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DWG/PIN
Description: Patients assigned to this arm will undergo dorsal wrist ganglion excision and the addition of a partial wrist denervation by resecting the common terminal sensory branch of the posterior interosseus nerve (PIN)..
Study NCT04703686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000mg - prephase - one infusion at D-3
Study NCT04703686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7082859
Description: 2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
Study NCT06791616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Surveillance colonoscopy
Study NCT06791616 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Surveillance colonoscopy
Study NCT06792617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobility (Central or Femoral Cannulation)
Description: Functional Mobility \& ADL's~1. Assisted sitting with progression to unassisted; ADL's~2. Assisted standing with progression to unassisted; ADL's~   1. VitalGo bed will be used if unsafe/unable to perform assisted standing.~  2. Leg press (VitalGo bed)~3. Ambulation; ADL's
Study NCT06792617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Training
Description: Repetitions will be counted and documented per session per structured exercise.
Study NCT06791213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Multimedia Health Education
Description: This study aims to investigate the effectiveness of digital multimedia in reducing pain, enhancing medication adherence, and improving pain control satisfaction among patients. The goal is to overcome the limitations of busy healthcare providers, allowing patients to learn independently, understand pain and analgesic use, dispel myths about pain medications, and enhance pain control, ultimately improving self-care capabilities, pain control satisfaction, and quality of life.
Study NCT06792175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Solicue Machine Learning Models
Description: A comprehensive machine-learning tool aimed at providing probability estimates for several compatible disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Bipolar Affective Disorder (BPAD), Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia Spectrum Disorders (SSD). By offering a multi-diagnostic assessment based on speech analysis, Solicue aims to assist clinicians in navigating this complexity and potentially identifying conditions that might otherwise be overlooked in initial assessments.~Solicue leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features.
Study NCT06792175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mercuria Machine Learning Models
Description: Mercuria is designed to stratify the risk of bipolar disorder in individuals presenting with depressive symptoms. This is a critical clinical need, as misdiagnosis of bipolar disorder as unipolar depression is common and can lead to inappropriate treatment, potentially worsening outcomes. By analyzing speech patterns characteristic of bipolar disorder, Mercuria aims to provide an additional tool for clinicians to differentiate between these conditions more accurately, guiding appropriate treatment decisions.~Mercuria leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features.
Study NCT06790875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Description: In this arm, participants will receive airway pressure release ventilation (APRV), a form of pressure-controlled mechanical ventilation. The high pressure (Phigh) is set based on the plateau pressure of the LTV mode, with a low pressure (Plow) set at 0 cmH₂O. The high pressure time (Thigh) will be set to 4-6 seconds to maintain alveolar recruitment, while the low pressure time (Tlow) will be set to 0.2-0.6 seconds to optimize expiratory flow. This arm aims to evaluate the effects of APRV on lung tissue mechanics, oxygenation, and overall respiratory function in ARDS patients.
Study NCT05330936 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Potent topical steroid
Description: Cyanocobalamin in Avocado Oil Cream
Study NCT06790537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Description: 75 mg of pregabalin will be given at night for the intervention group along with emollient local application